Fulltext

Koenimbin, a natural dietary compound of Murraya koenigii (L) Spreng: inhibition of MCF7 breast cancer cells and targeting of derived MCF7 breast cancer stem cells (CD44(+)/CD24(-/low)): an in vitro study

Ahmadipour F 1 , Noordin MI 1 , Mohan S 2 , Arya A 1 , Paydar M 3 , Looi CY 3 Show all authors , Keong YS 4 , Siyamak EN 4 , Fani S 1 , Firoozi M 5 , Yong CL 1 , Sukari MA 6 , Kamalidehghan B 1

Affiliations 

  • 1 Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 2 Medical Research Center, Jazan University, Jazan, Kingdom of Saudi Arabia
  • 3 Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 4 UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Malaysia
  • 5 Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran
  • 6 Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Malaysia
Drug Des Devel Ther, 2015;9:1193-208.
PMID: 25759564 DOI: 10.2147/DDDT.S72127

Abstract

Inhibition of breast cancer stem cells has been shown to be an effective therapeutic strategy for cancer prevention. The aims of this work were to evaluate the efficacy of koenimbin, isolated from Murraya koenigii (L) Spreng, in the inhibition of MCF7 breast cancer cells and to target MCF7 breast cancer stem cells through apoptosis in vitro.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications